c-Kit-positive ILC2s exhibit an ILC3-like signature that may contribute to IL-17-mediated pathologies.


Journal

Nature immunology
ISSN: 1529-2916
Titre abrégé: Nat Immunol
Pays: United States
ID NLM: 100941354

Informations de publication

Date de publication:
08 2019
Historique:
received: 22 05 2018
accepted: 15 05 2019
pubmed: 3 7 2019
medline: 20 11 2019
entrez: 3 7 2019
Statut: ppublish

Résumé

Here we identify a group 2 innate lymphoid cell (ILC2) subpopulation that can convert into interleukin-17 (IL-17)-producing NKp44

Identifiants

pubmed: 31263279
doi: 10.1038/s41590-019-0423-0
pii: 10.1038/s41590-019-0423-0
doi:

Substances chimiques

CCR10 protein, human 0
IL17A protein, human 0
IL1B protein, human 0
IL23A protein, human 0
IL4 protein, human 0
Interleukin-17 0
Interleukin-1beta 0
Interleukin-23 Subunit p19 0
Nuclear Receptor Subfamily 1, Group F, Member 3 0
RORC protein, human 0
Receptors, CCR10 0
Transforming Growth Factor beta 0
Interleukin-4 207137-56-2
KIT protein, human EC 2.7.10.1
Proto-Oncogene Proteins c-kit EC 2.7.10.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

992-1003

Commentaires et corrections

Type : ErratumIn

Auteurs

Jochem H Bernink (JH)

Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

Yoichiro Ohne (Y)

Department of Respiratory, Inflammation and Autoimmunity, MedImmune LLC, Gaithersburg, MD, USA.

Marcel B M Teunissen (MBM)

Department of Dermatology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

Jingya Wang (J)

Department of Respiratory, Inflammation and Autoimmunity, MedImmune LLC, Gaithersburg, MD, USA.

Jincheng Wu (J)

Department of Research Bioinformatics, MedImmune LLC, Gaithersburg, MD, USA.

Lisette Krabbendam (L)

Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

Christine Guntermann (C)

Autoimmunity, Transplantation, and Inflammation Disease Area, Novartis Institutes for BioMedical Research, Basel, Switzerland.

Richard Volckmann (R)

Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands.

Jan Koster (J)

Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands.

Sophie van Tol (S)

Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

Ivan Ramirez (I)

Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

Yashaswi Shrestha (Y)

Department of Translational Medicine and Pharmacogenomics, MedImmune LLC, Gaithersburg, MD, USA.

Menno A de Rie (MA)

Department of Dermatology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

Hergen Spits (H)

Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. hergen.spits@amc.uva.nl.

Xavier Romero Ros (X)

Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Department of Respiratory, Inflammation and Autoimmunity, MedImmune LLC, Gaithersburg, MD, USA.

Alison A Humbles (AA)

Department of Respiratory, Inflammation and Autoimmunity, MedImmune LLC, Gaithersburg, MD, USA. alisonhumbles@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH